Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viridian Therapeutics, Inc.

13.53
+0.03000.22%
Pre-market: 13.15-0.3800-2.81%04:07 EDT
Volume:683.51K
Turnover:9.25M
Market Cap:1.10B
PE:-4.40
High:13.96
Open:13.40
Low:13.27
Close:13.50
Loading ...

US FDA Animal Testing De-Emphasis May Boost Biotech Innovation, RBC Says

MT Newswires Live
·
11 Apr

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Business Wire
·
07 Apr

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)

TIPRANKS
·
04 Apr

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
10 Mar

BRIEF-Viridian Therapeutics Terminates Prior $175 Million Sale Agreement

Reuters
·
04 Mar

Viridian Therapeutics Inc - Enters $300 Million Sale Agreement With Jefferies

THOMSON REUTERS
·
04 Mar

Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges

TIPRANKS
·
04 Mar

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC) and Viridian Therapeutics (VRDN)

TIPRANKS
·
28 Feb

Viridian Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Wedbush Cuts Price Target on Viridian Therapeutics to $46 From $48, Keeps Outperform Rating

MT Newswires Live
·
27 Feb

Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Vertex Pharmaceuticals (VRTX) and Viridian Therapeutics (VRDN)

TIPRANKS
·
27 Feb

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $1.05 Loss

MT Newswires Live
·
27 Feb

Viridian Therapeutics: Strong Cash Position of $717.6 Mln as of Dec 31, 2024; Provides Cash Runway Into H2 2027

THOMSON REUTERS
·
27 Feb

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire
·
27 Feb

Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt?

Simply Wall St.
·
11 Feb

BRIEF-Viridian Therapeutics Appoints Seth Harmon As CFO

Reuters
·
11 Jan

Viridian Therapeutics Inc - on Jan 7, Board Appoints Seth Harmon as CFO

THOMSON REUTERS
·
11 Jan

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Business Wire
·
08 Jan

Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham

Dow Jones
·
07 Jan

Top Calls on Wall Street: Micron, C3.ai, Palantir, Block, SentinelOne, Western Digital, and More

The Fly
·
19 Dec 2024